Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2482629 | 0.86 | MCL1 (0.31) | MCL1 | |
| SCHEMBL31567182 | 0.75 | MCL1 (0.32) | MCL1 | |
| SCHEMBL6835334 | 0.74 | TSHR (0.39) | — | |
| SCHEMBL31567419 | 0.72 | MCL1 (0.31) | MCL1 | |
| SCHEMBL769792 | 0.72 | DGAT1 (0.34) | — | |
| SCHEMBL9755812 | 0.71 | MCL1 (0.34) | MCL1 | |
| SCHEMBL26121759 | 0.69 | MCL1 (0.50) | MCL1 | |
| SCHEMBL9713568 | 0.69 | MCL1 (0.41) | MCL1 | |
| SCHEMBL769718 | 0.69 | MCL1 (0.39) | MCL1 | |
| SCHEMBL222826 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551963-B2 | Imidazolothiazole compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551963-B2 | Imidazolothiazole compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551963-B2 | Imidazolothiazole compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-22 | — | — | US | disclosed |
| EP-2358725-A1 | Imidazolothiazole compounds as modulators of protein kinase | Ambit Biosciences Corporation (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010054058-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AS MODULATORS OF PROTEIN KINASE | AMBIT BIOSCIENCE CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GRK2, GRK3, GRK4 | MCL1 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.